Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR‐2 retrospective chart review study

• DOI: 10.1111/bjh.18519
• Publication Date: 2022-10-19T02:26:40Z
• Authors: Georg Hess; Martin Dreyling; Lucie Oberic; Eva Gine; Pier Luigi Zinzani; Kim Linton; Adam Vilmar; Mats Jerkeman; Jenny M. H. Chen; Anke Ohler; Stephan Stilgenbauer; Catherine Thieble...; Jonathan Lambert; Vittorio Ruggero ...; Juan‐Manuel Sancho; Ana Jiménez‐Ubieto; Luca Fischer; Toby A. Eyre; Sam Keeping; Julie E. Park; James J. Wu; Rubina Siddiqi; John Reitan; Sally Wade; Gilles Salles
• Keywords: Real-world evidence; Adult; Bruton tyrosine kinase inhibitor; mantle cell lymphoma; post-BTKi; real-world evidence; survival; Mantle cell lymphoma; Survival; mantle cell lymphoma; post-BTKi; Lymphoma, Mantle-Cell; Tyrosine Kinase Inhibitors; Bruton tyrosine kinase inhibitor; survival; 3. Good health; Europe; 03 medical and health sciences; 0302 clinical medicine; Humans; Neoplasm Recurrence, Local; real-world evidence; Retrospective Studies

Summary Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. This multicentre retrospective chart review study, SCHOLAR‐2, addresses this knowledge gap reports on data collected from 240 relapsed/refractory MCL Europe were treated BTKi‐based therapy between July 2012 2018, had experienced disease progression while BTKi or discontinued due to intolerance. The median overall survival (OS) initiation first was 14.6 months (95% confidence interval [CI] 11.6–20.0) the cohort, 5.5 CI 3.9–8.2) 91 without post‐BTKi therapy, 23.8 18.9–30.1) 149 received (excluding chimeric antigen receptor T‐cell treatment). In latter group, a one (range, seven) line lenalidomide‐containing regimens bendamustine plus rituximab being most frequently administered; OS 9.7 6.3–12.7). These results provide benchmark R/R receiving salvage failure.